Literature DB >> 22024159

The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder.

Ke Wu1, Gregory L Hanna, David R Rosenberg, Paul D Arnold.   

Abstract

Obsessive-compulsive disorder (OCD) is a common and often debilitating neuropsychiatric condition characterized by persistent intrusive thoughts (obsessions), repetitive ritualistic behaviors (compulsions) and excessive anxiety. While the neurobiology and etiology of OCD has not been fully elucidated, there is growing evidence that disrupted neurotransmission of glutamate within corticalstriatal-thalamocortical (CSTC) circuitry plays a role in OCD pathogenesis. This review summarizes the findings from neuroimaging, animal model, candidate gene and treatment studies in the context of glutamate signaling dysfunction in OCD. First, studies using magnetic resonance spectroscopy are reviewed demonstrating altered glutamate concentrations in the caudate and anterior cingulate cortex of patients with OCD. Second, knockout mouse models, particularly the DLGAP3 and Sltrk5 knockout mouse models, display remarkably similar phenotypes of compulsive grooming behavior associated with glutamate signaling dysfunction. Third, candidate gene studies have identified associations between variants in glutamate system genes and OCD, particularly for SLC1A1 which has been shown to be associated with OCD in five independent studies. This converging evidence for a role of glutamate in OCD has led to the development of novel treatment strategies involving glutamatergic compounds, particularly riluzole and memantine. We conclude the review by outlining a glutamate hypothesis for OCD, which we hope will inform further research into etiology and treatment for this severe neuropsychiatric condition.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22024159      PMCID: PMC3437220          DOI: 10.1016/j.pbb.2011.10.007

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  114 in total

1.  Memantine as an augmenting agent for severe pediatric OCD.

Authors:  Dianne M Hezel; Katherine Beattie; S Evelyn Stewart
Journal:  Am J Psychiatry       Date:  2009-02       Impact factor: 18.112

2.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

3.  Thalamic volume in pediatric obsessive-compulsive disorder patients before and after cognitive behavioral therapy.

Authors:  D R Rosenberg; N R Benazon; A Gilbert; A Sullivan; G J Moore
Journal:  Biol Psychiatry       Date:  2000-08-15       Impact factor: 13.382

4.  Facilitation of conditioned fear extinction by systemic administration or intra-amygdala infusions of D-cycloserine as assessed with fear-potentiated startle in rats.

Authors:  David L Walker; Kerry J Ressler; Kwok-Tung Lu; Michael Davis
Journal:  J Neurosci       Date:  2002-03-15       Impact factor: 6.167

5.  Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study.

Authors:  Liza B Green; Joseph E Hornyak; Edward A Hurvitz
Journal:  Am J Phys Med Rehabil       Date:  2004-12       Impact factor: 2.159

Review 6.  Multiple rare SAPAP3 missense variants in trichotillomania and OCD.

Authors:  S Züchner; J R Wendland; A E Ashley-Koch; A L Collins; K N Tran-Viet; K Quinn; K C Timpano; M L Cuccaro; M A Pericak-Vance; D C Steffens; K R Krishnan; G Feng; D L Murphy
Journal:  Mol Psychiatry       Date:  2009-01       Impact factor: 15.992

7.  Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder.

Authors:  S Evelyn Stewart; Jesen A Fagerness; Jill Platko; Jordan W Smoller; Jeremiah M Scharf; Cornelia Illmann; Eric Jenike; Nadia Chabane; Marion Leboyer; Richard Delorme; Michael A Jenike; David L Pauls
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-12-05       Impact factor: 3.568

8.  Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

Authors:  Jamie D Feusner; Lauren Kerwin; Sanjaya Saxena; Alexander Bystritsky
Journal:  Psychopharmacol Bull       Date:  2009

9.  'Compulsive' lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam.

Authors:  D Joel; E Ben-Amir; J Doljansky; S Flaisher
Journal:  Behav Pharmacol       Date:  2004-05       Impact factor: 2.293

10.  Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice.

Authors:  Sergey V Shmelkov; Adília Hormigo; Deqiang Jing; Catia C Proenca; Kevin G Bath; Till Milde; Evgeny Shmelkov; Jared S Kushner; Muhamed Baljevic; Iva Dincheva; Andrew J Murphy; David M Valenzuela; Nicholas W Gale; George D Yancopoulos; Ipe Ninan; Francis S Lee; Shahin Rafii
Journal:  Nat Med       Date:  2010-04-25       Impact factor: 53.440

View more
  61 in total

1.  Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial.

Authors:  Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi
Journal:  Neuropsychopharmacology       Date:  2017-04-04       Impact factor: 7.853

Review 2.  Learning From Animal Models of Obsessive-Compulsive Disorder.

Authors:  Patricia Monteiro; Guoping Feng
Journal:  Biol Psychiatry       Date:  2015-05-04       Impact factor: 13.382

Review 3.  Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective.

Authors:  David L Pauls; Amitai Abramovitch; Scott L Rauch; Daniel A Geller
Journal:  Nat Rev Neurosci       Date:  2014-06       Impact factor: 34.870

4.  A CASE OF PERIPARTUM OBSESSIVE-COMPULSIVE DISORDER: The Potential Role of Corticosteroids, Gonadal Steroids, and the Neuropeptide Oxytocin in its Pathogenesis.

Authors:  David R Spiegel; Kathyrn Sommese; Anastasia Turenkov; Niels Naimon
Journal:  Innov Clin Neurosci       Date:  2019-05-01

5.  Significant concordance of genetic variation that increases both the risk for obsessive-compulsive disorder and the volumes of the nucleus accumbens and putamen.

Authors:  Derrek P Hibar; Joshua W Cheung; Sarah E Medland; Mary S Mufford; Neda Jahanshad; Shareefa Dalvie; Raj Ramesar; Evelyn Stewart; Odile A van den Heuvel; David L Pauls; James A Knowles; Dan J Stein; Paul M Thompson
Journal:  Br J Psychiatry       Date:  2018-07       Impact factor: 9.319

6.  12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.

Authors:  Paul J Grant; Lisa A Joseph; Cristan A Farmer; David A Luckenbaugh; Lorraine C Lougee; Carlos A Zarate; Susan E Swedo
Journal:  Neuropsychopharmacology       Date:  2013-12-19       Impact factor: 7.853

7.  In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

Authors:  Mohammad Haghighi; Leila Jahangard; Hamid Mohammad-Beigi; Hafez Bajoghli; Hassan Hafezian; Alireza Rahimi; Hamid Afshar; Edith Holsboer-Trachsler; Serge Brand
Journal:  Psychopharmacology (Berl)       Date:  2013-03-23       Impact factor: 4.530

Review 8.  Anxiety and affective disorder comorbidity related to serotonin and other neurotransmitter systems: obsessive-compulsive disorder as an example of overlapping clinical and genetic heterogeneity.

Authors:  Dennis L Murphy; Pablo R Moya; Meredith A Fox; Liza M Rubenstein; Jens R Wendland; Kiara R Timpano
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

Review 9.  Genetic susceptibility and neurotransmitters in Tourette syndrome.

Authors:  Peristera Paschou; Thomas V Fernandez; Frank Sharp; Gary A Heiman; Pieter J Hoekstra
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

10.  Glutamate system genes and brain volume alterations in pediatric obsessive-compulsive disorder: a preliminary study.

Authors:  Ke Wu; Gregory L Hanna; Philip Easter; James L Kennedy; David R Rosenberg; Paul D Arnold
Journal:  Psychiatry Res       Date:  2012-11-13       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.